Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab. Reumatismo, [S. l.], v. 77, n. 3, 2025. DOI: 10.4081/reumatismo.2025.1792. Disponível em: https://www.reumatismo.org/reuma/article/view/1792. Acesso em: 19 sep. 2025.